

SEPTEMBER 2020 PBAC MEETING – POSITIVE RECOMMENDATIONS

DRUG, SPONSOR, TYPE OF SUBMISSION	DRUG TYPE OR USE	LISTING REQUESTED BY SPONSOR / PURPOSE OF SUBMISSION	PBAC OUTCOME
<p>RIFAMPICIN</p> <p>Capsule 150 mg Capsule 300 mg</p> <p>Rimycin 150® Rimycin 300®</p> <p>Alphapharm Pty Limited</p> <p>New listing (Matters outstanding)</p>	<p>Mycobacterium ulcerans infections (Buruli ulcer)</p>	<p>Request to extend the indication for rifampicin to include the treatment of Mycobacterium ulcerans infections (Buruli ulcer).</p>	<p>The PBAC recommended the Authority Required (Telephone/Electronic/Emergency) listing of rifampicin for the treatment of Mycobacterium ulcerans infection (Buruli ulcer), noting that treatment must be used in combination with another antibiotic for the treatment of Buruli ulcer.</p>